Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2026)
Denali Therapeutics (DNLI) reported Return on Capital Employed of 49.95% for Q1 2026, down 810.0% year-over-year from 7.04% in Q1 2025, and up 9.88% quarter-over-quarter from 55.43% in Q4 2025.
Denali Therapeutics (DNLI) Return on Capital Employed (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 9 years of Return on Capital Employed data on file, last reported at 49.95% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 49.95%, down 810.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 49.95% (down 810.0% YoY), and the FY2025 annual result was 47.83%, down 588.0% from the prior year.
- Return on Capital Employed grew to 49.95% in Q1 2026 per DNLI's latest filing, from 55.43% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 12.67% in Q2 2023 and troughed at 55.43% in Q4 2025.
- A 5-year average of 34.06% and a median of 34.77% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed tumbled 3653 bps in 2022, then surged 2278 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 34.77% in 2022, then soared by 49 bps to 17.6% in 2023, then slumped by 111 bps to 37.15% in 2024, then tumbled by 49 bps to 55.43% in 2025, then climbed by 10 bps to 49.95% in 2026.
- Business Quant data shows DNLI's Return on Capital Employed at 49.95% in Q1 2026, 55.43% in Q4 2025, and 53.67% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | -49.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.95% |
| Dec 31, 2025 | -55.43% |
| Sep 30, 2025 | -53.67% |
| Jun 30, 2025 | -47.31% |
| Mar 31, 2025 | -41.86% |
| Dec 31, 2024 | -37.15% |
| Sep 30, 2024 | -35.23% |
| Jun 30, 2024 | -32.76% |
| Mar 31, 2024 | -15.07% |
| Dec 31, 2023 | -17.60% |
| Sep 30, 2023 | -14.12% |
| Jun 30, 2023 | -12.67% |
| Mar 31, 2023 | -37.85% |
| Dec 31, 2022 | -34.77% |
| Sep 30, 2022 | -34.75% |
| Jun 30, 2022 | -30.32% |
| Mar 31, 2022 | -28.50% |
| Dec 31, 2021 | -28.20% |
| Sep 30, 2021 | 1.79% |
| Jun 30, 2021 | 3.45% |